OncoMatch/Bile Duct Cancer (Cholangiocarcinoma)/FGFR2
Bile Duct Cancer (Cholangiocarcinoma)FGFR2 Clinical Trials
FGFR2 fusions or rearrangements occur in approximately 15–20% of intrahepatic cholangiocarcinoma (iCCA) and are the most clinically actionable alteration in this disease. Pemigatinib and futibatinib are FDA-approved for FGFR2-fusion-positive previously treated iCCA; a third agent (infigratinib) had its approval voluntarily withdrawn in 2023. Trials investigate FGFR2-targeted agents in the first-line setting, mechanisms of acquired resistance (V565F gatekeeper mutation), and combination strategies with checkpoint inhibitors.
Top recruiting FGFR2 Bile Duct Cancer (Cholangiocarcinoma) trials
Ranked by phase and US site count. See all 8 trials matched to your profile →
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences, Inc.
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Taiho Oncology, Inc.
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Mehmet Akce
Pemigatinib in the Advanced Gastrointestinal Cancer With FGFR 1-3 Alterations
Tianjin Medical University Cancer Institute and Hospital
A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Beijing InnoCare Pharma Tech Co., Ltd.
Browse other molecular targets with active Bile Duct Cancer (Cholangiocarcinoma) trials.